Ascilion AB, a global leader in dermal interstitial fluid (dISF) sampling, will present cutting-edge research and unveil its latest product innovations at MICRONEEDLES 2025 in Brisbane, taking place from May 11-14.

Ascilion’s participation in the 8th International Microneedles Conference underscores its pioneering work in hollow microneedle technology for biomarker investigation. The company’s experts, alongside clinical partners, will deliver three oral and three poster presentations covering topics such as:

• Unique biomarker profiles in dISF versus plasma
• Antigen discovery in cold urticaria using microneedles
• dISF extraction in heart failure patients within the DIGIPREDICT project
• Commercialization challenges in diagnostic microneedles
• Biomolecule extraction from skin for chronic urticaria and allergy applications
• Reliable dISF sampling as a driver for innovation

“Ascilion is proud to return to this premier event for the fifth time, sharing years of groundbreaking research and clinical insights,” said Markus Renlund, Founder of Ascilion. CEO Simon Grant added, “We are at the forefront of diagnostic microneedle technology and excited to discuss our commercialization journey with the global scientific and business community.”

Ascilion’s flagship product, PELSA, enables rapid and painless dISF sampling for biomarker evaluation in pharmaceutical and cosmetic research. The company continues to drive innovation, working closely with industrial partners and researchers to advance the field.

For more information, visit www.ascilion.com.

For more details and to register, visit https://swiftnlift.com/contact/

Media Contact:
[Swiftnlift Business Magazine]
[pressrelease@swiftnlift.com]
[+1 6143622384 / +1 6145693002]